Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is set to present at the World Orphan Drug Congress USA 2022 from August 25-27, 2022. Dr. David Young, CEO, will discuss 'Balancing the Benefit-Risk of an Orphan Drug: Case Studies' on August 25 at 1:30 PM ET. The company's mission focuses on developing treatments for patients with unmet medical needs, showcasing three drugs in clinical development targeting various cancers and other conditions. For more details, visit www.ProcessaPharma.com.
- None.
- None.
HANOVER, MD, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition today announced it will present at the World Orphan Drug Congress USA 2022 Conference, to be held from August 25-27, 2022.
Dr. David Young, CEO and Chairman of Processa will deliver a presentation titled “Balancing the Benefit-Risk of an Orphan Drug: Case Studies.”
Presentation Details:
Date: Wednesday, August 25, 2021
Time: 1:30 PM Eastern Time
Website: https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/index.stm
About Processa Pharmaceuticals, Inc.
Our mission is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need conditions. We are a development company, not a discovery company, that seeks to identify and develop drugs for patients who need better treatment options than presently exist for their medical condition. To increase the probability of development success, our pipeline only includes drugs which have previously demonstrated some efficacy in the targeted population or a drug with very similar pharmacological properties has been shown to be effective in the population.
We currently have three drugs in various stages of clinical development: PCS499 for Ulcerative Necrobiosis in Phase 2B; PCS3117 for metastatic pancreatic cancer and non-small cell lung cancer in Phase 2B; and PCS6422 for metastatic colorectal cancer and breast cancer in Phase 1B. The PCS12852 IND for the treatment of gastroparesis will be submitted in 3Q2021.
Members of the Processa development team throughout their careers have been involved with more than 30 FDA drug approvals (including drug products targeted to orphan disease conditions), more than 100 FDA meetings, and two FDA regulatory science contracts. For more information, visit the company’s website at www.ProcessaPharma.com.
For More Information:
Michael Floyd
mfloyd@processapharma.com
(301) 651-4256
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
FAQ
What is the date and time of Processa Pharmaceuticals' presentation at the World Orphan Drug Congress USA 2022?
Who will present at the World Orphan Drug Congress USA 2022 for PCSA?
What is the focus of Processa Pharmaceuticals' presentation at the conference?
Where can I find more information about Processa Pharmaceuticals?
What types of drugs is Processa Pharmaceuticals developing?
